Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study-Reference-Cited by-同舟云学术

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

Published:2013-05-16 Issue:20 Volume:121 Page:4046-4055
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gouw Samantha C.¹,van den Berg H. Marijke²,Fischer Kathelijn²³,Auerswald Günter⁴,Carcao Manuel⁵,Chalmers Elizabeth⁶,Chambost Hervé⁷,Kurnik Karin⁸,Liesner Ri⁹,Petrini Pia¹⁰,Platokouki Helen¹¹,Altisent Carmen¹²,Oldenburg Johannes¹³,Nolan Beatrice¹⁴,Garrido Rosario Pérez¹⁵,Mancuso M. Elisa¹⁶,Rafowicz Anne¹⁷,Williams Mike¹⁸,Clausen Niels¹⁹,Middelburg Rutger A.²⁰,Ljung Rolf²¹,van der Bom Johanna G.²⁰²²

Affiliation:

1. Department of Paediatrics, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands;

2. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands;

3. Van Creveldkliniek, University Medical Center Utrecht, Utrecht, The Netherlands;

4. Gesundheit Nord, Klinikum Bremen Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany;

5. Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada;

6. Department of Haematology, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK;

7. Service d’hématologie pédiatrique, Hôpital La Timone & Aix-Marseille Univ, Marseille, France;

8. Dr. v. Haunersches Kinderspital, University of Munich, Munich, Germany;

9. Hemophilia Center, Department of Haematology, Great Ormond Street Hospital for children, London, UK;

10. Department of Pediatrics, Clinic of Coagulation Disorders, Karolinska Hospital, Stockholm, Sweden;

11. St. Sophia Children’s Hospital, Haemophilia-Haemostasis Unit, Athens, Greece;

12. Unitat Hemofilia, Hospital Traumatologica, Hospital Vall d’Hebron, Barcelona, Spain;

13. Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn, Bonn, Germany;

14. Department of Paediatric Haematology, St. James's Hospital, Dublin, Ireland;

15. Hospital General Unidad de Hemofilia, Hospitales Universitarios Virgen del Rocio, Sevilla, Spain;

16. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy;

17. Centre Régional de Traitement de l'Hémophilie et Autres Maladies Bicetre, Service Hématologique, Paris, France;

18. Department of Haematology, The Children’s Hospital, Birmingham, UK;

19. Department of Pediatrics, University Hospital of Aarhus at Skejby, Aarhus, Denmark;

20. Center for Clinical Transfusion Research, Sanquin Foundation, Leiden, The Netherlands;

21. Department of Pediatrics and Malmö Centre for Thrombosis and Haemostasis, Skånes Universitetssjukhus, Malmö, Sweden; and

22. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

Abstract

Key Points High-dose intensive factor VIII treatment increases the risk for inhibitor development in patients with severe hemophilia A. In patients with severe hemophilia A, factor VIII prophylaxis decreases inhibitor risk, especially in patients with low-risk F8 mutations.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/20/4046/531085/4046.pdf

Reference32 articles.

1. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management).;Donadel-Claeyssens;Haemophilia,2006

2. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.;Manco-Johnson;N Engl J Med,2007

3. The epidemiology of inhibitors in haemophilia A: a systematic review.;Wight;Haemophilia,2003

4. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A.;Leissinger;Haemophilia,2011

5. Haemophilia A: mutation type determines risk of inhibitor formation.;Schwaab;Thromb Haemost,1995

Cited by 270 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Balancing anticoagulation and hemostasis in an infant with severe hemophilia A during cardiac transplantation: Review of the literature and development of a surgical protocol;Pediatric Blood & Cancer;2023-11-07

2. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?;Journal of Thrombosis and Haemostasis;2023-11

3. Risk factors for coagulation inhibitor development in children with severe hemophilia A;Pediatric Hematology/Oncology and Immunopathology;2023-09-30

4. Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy;Haemophilia;2023-09-14

5. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09